Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.

Authors

Rachel Fremont, Marcella Corwin, Greta Kandel, Esha Talati, Jakub Denkiewicz, Rae L Sustana, Keren Bachi, Adriana Feder

Published in

Focus (American Psychiatric Publishing). Volume 24. Issue 2. Pages 115-126. Epub Apr 04, 2026.

Abstract

Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the authors describe recent advances in the use of ketamine and esketamine for the treatment of depression and other psychiatric disorders, new research on novel treatment targets, and emerging evidence about ketamine's potential as a prophylactic intervention. Key outstanding issues and limitations of current ketamine treatment also are discussed.

PMID:
42538887
Bibliographic data and abstract were imported from PubMed on 01 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.